CD274 and pancreatic neoplasm: Although some early success has been achieved with monotherapies blocking PD-1 pathways, the efficacy of an anti-PD-1/PD-L1 monotherapy may be ineffective when treating pancreatic cancer in an immune system suppressed by high tumor burden and intrinsic nonimmunogenic nature [73].